Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost.
Ignacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.
The U of U Health is the Mountain West’s only academic health care system, combining patient care, research, and teaching. Our News Room highlights breakthroughs in research, conferences, and also useful information for patients and people interested in general health topics.